Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q4 2025 | -61.81% |
| Q3 2025 | 2319.50% |
| Q2 2025 | 111.42% |
| Q1 2025 | -36.55% |
| Q4 2024 | -333.46% |
| Q3 2024 | 86.18% |
| Q2 2024 | -160.26% |
| Q1 2024 | 373.60% |
| Q4 2023 | 277.05% |
| Q3 2023 | -548.60% |
| Q2 2023 | -94.54% |
| Q1 2023 | 339.91% |
| Q4 2022 | -4427.97% |
| Q3 2022 | 145.14% |
| Q2 2022 | 94.18% |
| Q1 2022 | -184.07% |
| Q4 2021 | -139.47% |
| Q3 2021 | -55.34% |
| Q2 2021 | 69.70% |
| Q1 2021 | 214.29% |
| Q4 2020 | 185.97% |
| Q3 2020 | -130.34% |
| Q2 2020 | 191.53% |
| Q1 2020 | -227.64% |
| Q4 2019 | 51.71% |
| Q3 2019 | -5.77% |
| Q2 2019 | -102.16% |
| Q1 2019 | 1668.52% |
| Q4 2018 | -163.07% |
| Q3 2018 | -7.93% |
| Q2 2018 | 61.58% |
| Q1 2018 | 745.92% |
| Q4 2017 | -183.19% |
| Q3 2017 | 39.09% |
| Q2 2017 | 19.28% |
| Q1 2017 | 262.53% |
| Q4 2016 | -585.25% |
| Q3 2016 | 111.17% |
| Q2 2016 | -187.21% |
| Q1 2016 | 4.21% |